A study in healthy males to investigate a new pain relief drug

• Research type

  Research Study

• Full title

  A single center, randomized, three-part study in healthy young male subjects comprising a double-blind, placebo controlled, ascending single oral dose study to assess the safety, tolerability and pharmacokinetics of ASP9226, including an open-label comparison of pharmacokinetics under fasted and fed conditions, and an open-label single oral dose evaluation in CYP2D6 poor metabolizers

• IRAS ID

  85879

• Contact name

  John Lambert

• Contact email

  john.lambert@parexel.com

• Sponsor organisation

  Astellas Pharma Europe B.V. (APEB)

• Eudract number

  2011-002105-30

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• Research summary

  Research Summary not published at request of researcher

• REC name

  South Central - Berkshire B Research Ethics Committee

• REC reference

  11/IE/0095

• Date of REC Opinion

  15 Sep 2011

• REC opinion

  Further Information Favourable Opinion